WHO Essential Medicines and Health Products Department Update
- Slides: 5
WHO Essential Medicines and Health Products Department Update WHO EMP July – Dec 2014 IPC Meeting World Bank, Washington DC, December 16 - 17, 2014 Dr Kees de Joncheere 1| TITLE from VIEW and SLIDE MASTER | November 2020
1 - Access to Essential Medicines and other Health Technologies Area a) Involvement of WHO in Ebola Response for the last 6 months: R&D activities, preparedness and response in the field. b) Ebola and the challenges of the HS reconstruction including Pharmaceutical Systems: c) For the Assessment of procurement agencies: -ECSPP adopted the WHO Model quality assurance system. (MQAS) Ø Model inspection report Ø Revised product questionnaire (“interagency questionnaire”) 2| TITLE from VIEW and SLIDE MASTER | November 2020
1 - Access to Essential Medicines and other Health Technologies Area d) Preparation for the 10 years Good Governance in Medicines Programme; e) Medicines Transparency Alliance (Me. TA) evaluation with participating countries; f) Preparation of the Expert Committee on Essential Medicines (April 2015): Ø Review of oncology medicines; Ø Hepatitis C Medicines; Ø Update TB drugs and ARV 3| TITLE from VIEW and SLIDE MASTER | November 2020
1 - Access to Essential Medicines and other Health Technologies Area g) Medicines and UHC: Issue paper on high cost medicines and role of the HTA; h) Preparation of the Global Action Plan on the AMR: Meeting hosted by Norway on responsible use of antibiotics (Nov. 2014) 4| TITLE from VIEW and SLIDE MASTER | November 2020
2 - Regulatory issues: Quality, Safety and Efficacy a) Statement on value added of PQ; last updates on PQ for diagnostics and vaccines: b) MSM on SSFFC October 2014; - New study on Public health and economic impact of SSFFC - Prioritized workplan c) ICDRA: meeting in Brazil in August 2014. Pre meeting on Biosimilars. d) NRA Assesssment Tool: Consultation January 2015 5| TITLE from VIEW and SLIDE MASTER | November 2020
